Prodotto aggiunto correttamente al carrello.

discount label
H-SNTSESF-NH2
Visualizzare in 3D

Biosynth logo

H-SNTSESF-NH2

Rif. 3D-PP48195

Dimensione non definitaPrezzo su richiesta
Consegna stimata in Stati Uniti, il Martedì 10 Dicembre 2024

Informazioni sul prodotto

Nome:
H-SNTSESF-NH2
Descrizione:

Peptide H-SNTSESF-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SNTSESF-NH2 include the following: Nanomedicine strategies for heating"cold" ovarian cancer (OC): next evolution in immunotherapy of OC Y Yang, T Zhao, Q Chen, Y Li, Z Xiao - Advanced , 2022 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/advs.202202797 A Bispecific Peptide-Polymer Conjugate Bridging Target-Effector Cells to Enhance Immunotherapy W Zhang, D Li, X Xu, Y Chen, X Shi - Advanced , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202202977 Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway T Wang, X Wu, C Guo, K Zhang, J Xu - Journal of medicinal , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00990 The Synthesis and Anti-tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEE-G) Scaffolds with Multiple PD-1 Peptides Attached R Shrestha , EV Petley, KJ Farrand - , 2020 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202000221 The synthesis of potential drug candidates based on the PEE-G dendrimer scaffold R Shrestha - 2019 - openaccess.wgtn.ac.nzhttps://openaccess.wgtn.ac.nz/articles/thesis/The_synthesis_of_potential_drug_candidates_based_on_the_PEE-G_dendrimer_scaffold/22777214 PD-1/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules Q Geng, P Jiao, P Jin, G Su, J Dong - Current Pharmaceutical , 2017 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cpd/2017/00000023/00000039/art00008 PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy PG Sasikumar, NS Sudarshan, S Adurthi - Communications , 2021 - nature.comhttps://www.nature.com/articles/s42003-021-02191-1 [68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study M Zhou, S Xiang, Y Zhao , Y Tang , J Yang, X Yin - European Journal of , 2024 - Springerhttps://link.springer.com/article/10.1007/s00259-023-06447-2 A Plant Virus Nanoparticle Toolbox to Combat Cancer K Hefferon, M Shahgolzari , A Yavari - pharmafocusasia.comhttps://www.pharmafocusasia.com/research-development/plant-virus-nanoparticle-toolbox Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor J Liu, G Wang, L Liu, R Wu, Y Wu, C Fang, X Zhou - Scientific reports, 2019 - nature.comhttps://www.nature.com/articles/s41598-019-54231-w Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy H Peng, X He, Q Wang - Frontiers in Immunology, 2022 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2022.1035997/full Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer G Kandasamy, Y Karuppasamy , UM Krishnan - Vaccines, 2023 - mdpi.comhttps://www.mdpi.com/2076-393X/11/2/458 Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy E Khatoon, D Parama , A Kumar , MS Alqahtani - Life Sciences, 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0024320522005276 VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses C Wu, X Cao , X Zhang - RSC Medicinal Chemistry, 2021 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2021/md/d1md00185j CA-170-a potent small-molecule PD-L1 inhibitor or not? B Musielak, J Kocik , L Skalniak , K Magiera-Mularz - Molecules, 2019 - mdpi.comhttps://www.mdpi.com/1420-3049/24/15/2804 Virus-like particles: a self-assembled toolbox for cancer therapy A Shahrivarkevishahi , LM Hagge, OR Brohlin - Materials Today , 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2468519422000374 Materials Today Chemistry A Shahrivarkevishahi , LM Hagge, OR Brohlin - Materials , 2022 - labs.utdallas.eduhttps://labs.utdallas.edu/gassensmith/files/2022/03/1-s2.0-S2468519422000374-main.pdf Chemically Tuned Virus Like Particles: From Cancer Therapy to Targeted Delivery A Shahrivarkevishahi - 2021 - utd-ir.tdl.orghttps://utd-ir.tdl.org/items/2c22f8e6-d588-43ac-95a3-5f2fced7a7e8 Plant viral nanoparticle conjugated with anti-PD-1 peptide for ovarian cancer immunotherapy A Gautam, V Beiss, C Wang , L Wang - International Journal of , 2021 - mdpi.comhttps://www.mdpi.com/1422-0067/22/18/9733

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP48195 H-SNTSESF-NH2

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".